Chemists have characterized the molecular structure of the intermediate stage of plaque-forming amyloid fibrils, believed to cause Alzheimer’s disease. The finding may lead to new drug targets for this and other amyloid diseases, such as Parkinson’s and Creutzfeldt-Jakob.